UGT1A1

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
Tuesday, April 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

Exscientia Business and Financial Update for the Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Federal Reserve Bank, Automation, Ovarian cancer, DSM-IV codes, CDK7, Learning, LSD1, Bill, Half-life, UGT1A1, International, Inflammation, Patient, EDT, G&A, Cancer, AI, Bristol Myers Squibb, IND, Medicine, Merck Group, Sumitomo Pharma, PKC, ID, GMT, MALT1, Acute leukemia, Pharmaceutical industry

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.
  • Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT.
  • This study has the potential to support the ongoing development of ‘539, Exscientia’s LSD1 inhibitor
    In July 2023, Exscientia launched EXCYTE-1, a first-of-its-kind prospective observational study in ovarian cancer.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .

Applied BioMath, LLC Announces Participation at AAPS 2023 PharmSci 360

Retrieved on: 
Thursday, October 19, 2023
Drug development, Science, Patient, Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, CSO, Bi-specific T-cell engager, Simulation, Doctor of Philosophy, AAPS, R, National Center for Advancing Translational Sciences, Messenger, UGT1A1, Biomarker, Translation, Crigler–Najjar syndrome, Pharmaceutical industry, Medical imaging, Management, Medical device

CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.

Key Points: 
  • CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.
  • Applied BioMath will participate in multiple presentations during the conference.
  • Joshua Apgar, PhD, Co-founder and CSO at Applied BioMath will give a Speaker Spotlight presentation entitled, "Evolving Clinical Pharmacology and Translational PK/PD Approaches for New Modalities" on Tuesday, October 24th from 9:30-10:30am.
  • To learn more about Applied BioMath, visit www.appliedbiomath.com .

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Biotechnology, Congress, UGT1A1, Preclinical development, LSD1, Machine learning, Abstract, Bilirubin, Risk, AML, European Society for Medical Oncology, ESMO, Differentiable function, MALT1, Tissue, BTK, Vivo, Significance, Pharmaceutical industry, Medical imaging

Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, 2023 in Madrid, Spain.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, 2023 in Madrid, Spain.
  • “We are excited to share new preclinical data on our precision-designed LSD1 and MALT1 inhibitors, which we introduced to our oncology pipeline earlier this year,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.
  • “We believe these compounds bear strong potential for differentiation, patient benefit and value creation.
  • This data underlines how Exscientia can bring together AI design and novel translational research capabilities to create better quality drug candidates.

Exscientia Details Pipeline Prioritisation Strategy

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Clinical Trials, Software, Pharmaceutical, Health, Data Management, Science, Oncology, Artificial Intelligence, Pancreatic cancer, Tissue, Carcinoma, LSD1, Partnership, Acute leukemia, ESMO, Therapeutic index, Pharmacokinetics, CDK7, Merck Group, Lung cancer, CNS, SCLC, AML, Investment, Patient, Standard of care, Colorectal cancer, Medicine, UGT1A1, A2A, Ovarian cancer, Automation, Pharmaceutical industry, Medical imaging

Exscientia plc (Nasdaq: EXAI) today provided an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today provided an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation.
  • Exscientia has built a highly efficient and versatile AI-led drug discovery platform.
  • This strategic focus is designed to allow Exscientia to maximise its pipeline value and output while continuing to develop novel technologies to transform drug discovery and development.
  • “Exscientia creates value by using technology to solve previously unsolved discovery challenges and achieving great data-driven operating efficiency,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.

Positive Phase 1/2 Clinical Trial Results of Genethon’s Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease, Published in The New England Journal of Medicine

Retrieved on: 
Tuesday, August 22, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Haemophilia, DSM-IV codes, PI, Nerve, The New England Journal of Medicine, Clinical trial, Quality of life, Crigler–Najjar syndrome, Academic Medical Center (Amsterdam), Research, Creativity, Light, Jaundice, Bilirubin, UGT1A1, Liver, Ageing, Safety, Jeanne Labrune, Pharmaceutical industry, Patient

Genethon, a pioneer and leader in gene therapy research and development for rare genetic diseases, announced today positive Phase 1/2 clinical trial results of its gene therapy, GNT-0003, for Crigler-Najjar syndrome were published in The New England Journal of Medicine.

Key Points: 
  • Genethon, a pioneer and leader in gene therapy research and development for rare genetic diseases, announced today positive Phase 1/2 clinical trial results of its gene therapy, GNT-0003, for Crigler-Najjar syndrome were published in The New England Journal of Medicine.
  • The data demonstrate the possibility of restoring expression of liver enzyme UGT1A1 by using gene therapy in cases of Crigler-Najjar syndrome.
  • The Phase 1/2 trial results published in an article titled, “Gene Therapy in Patients with the Crigler-Najjar Syndrome,” showed GNT-0003 lowered bilirubin levels below the toxic threshold with a single intravenous injection.
  • This is the first proof of the efficacy of a gene therapy in a metabolic disease of the liver.

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Conference, Na'aran, Viral, RNA-dependent RNA polymerase, International Conference on Emerging Infectious Diseases, CNRS, ICAR, COVID-19, SLC, Rat, Doctor of Philosophy, CYP450, Urine, HIV disease progression rates, Cirrhosis, ABC, Antiviral Research, CET, SP, Drug resistance, Aix-Marseille University, SARS-CoV-2, Fever Dream, NS5A, BEM, Infection, Sulfur, Plasma, GUK1, Risk, ADME, Methylation, Enzyme, Patient, Metabolism, UGT1A1, Coronavirus, Phosphate, Safety, Discovery and development of NS5A inhibitors, RNA, Hepatitis C, Human coronavirus OC43, Combination, Virus, DENV, Maintenance, Architecture, GalNAc-T activation pathway, Feces, HINT1, Orthornavirae, Dengue virus, RZR, Therapy, NS5, Pharmaceutical industry, Vaccine, Flour, Phosphorus, Bemnifosbuvir, HCV

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of new Phase 1, in vitro and in vivo data that demonstrate key profile attributes of Atea’s lead drug candidate, bemnifosbuvir, for the treatment of COVID-19 and hepatitis C (HCV). Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented. These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.

Key Points: 
  • Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented.
  • These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.
  • These advantages include a higher barrier to resistance and maintenance of antiviral activity in the presence of COVID-19 variants.
  • Additionally, the combination of bemnifosbuvir and ruzasvir for the treatment of HCV demonstrated potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions.

Exscientia Announces Expansion of its Precision Oncology Pipeline

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Gene, LSD1, Bilirubin, Pharmacokinetics, CNS, Brain, CDK7, Therapeutic index, Bristol Myers Squibb, MALT1, Histone, Half-life, BMS, ADME, UGT1A1, Probability, Medicine, Safety, Carcinoma, A2A, Drug design, SCLC, Metabolism, Drug discovery, IND, Survival, PKC, Pharmaceutical industry

Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor.
  • Bristol Myers Squibb's options to the candidates have now lapsed and Exscientia maintains all worldwide rights to both compounds.
  • In 2021, an agreement was signed to expand the collaboration to include additional programmes in oncology and immunology.
  • Over the course of 2023, we expect to provide more details on these programmes as well as on our broader internal and partnered pipeline.”

Genethon Given PRIME Status by EMA for Gene Therapy To Treat Crigler-Najjar Syndrome, a Rare Liver Disease

Retrieved on: 
Tuesday, March 7, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PRIME, Blood, EMA, European Medicines Agency, Liver disease, Hepatology, Toxicity, Nerve, Immunology, Bilirubin, Death, UGT1A1, Crigler–Najjar syndrome, Gene, Light, AAV, Patient, Disease, Muscular Dystrophy Association, Safety, Pharmaceutical industry

Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), today announced that the European Medicines Agency (EMA) has granted PRIME (Priority Medicines) status to the gene therapy, GNT-0003, currently in clinical trials for Crigler-Najjar syndrome, a rare liver disease.

Key Points: 
  • Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), today announced that the European Medicines Agency (EMA) has granted PRIME (Priority Medicines) status to the gene therapy, GNT-0003, currently in clinical trials for Crigler-Najjar syndrome, a rare liver disease.
  • “We’re excited about the EMA’s PRIME recognition of GNT-0003,” said Genethon CEO Frederic Revah.
  • Crigler-Najjar syndrome is a rare genetic liver disease characterized by abnormally high levels of bilirubin in the blood (hyperbilirubinemia).
  • The gene therapy, administered intravenously, was designed by Genethon's Immunology and Gene Therapy of Liver Diseases team, led by Dr. Giuseppe Ronzitti.

Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease

Retrieved on: 
Tuesday, January 10, 2023
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Disease, Crigler–Najjar syndrome, Ageing, Institute of Liver and Biliary Sciences, Gene, Blood, Bilirubin, Toxicity, Muscular Dystrophy Association, AAV, Death, Safety, Academic Medical Center (Amsterdam), Nerve, Patient, Light, Research, Clinical trial, UGT1A1, Immunology, Pharmaceutical industry, Clamart

Genethon , a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), has launched a pivotal clinical trial in Europe for treatment of Crigler-Najjar syndrome, a life threatening liver disease.

Key Points: 
  • Genethon , a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), has launched a pivotal clinical trial in Europe for treatment of Crigler-Najjar syndrome, a life threatening liver disease.
  • “This new step demonstrates once again the excellence of the research conducted at Genethon, which is today one of the major players in gene therapy at the international level."
  • Crigler-Najjar syndrome is a rare genetic liver disease characterized by abnormally high levels of bilirubin in the blood (hyperbilirubinemia).
  • The gene therapy, administered intravenously, was designed by Genethon's Immunology and Gene Therapy of Liver Diseases team, led by Dr. Giuseppe Ronzitti.